Latest / The Science of Skin / Clinical Insights on P-TIOX: A Game Changer in Dermatology

Transcript

Clinical Insights on P-TIOX: A Game Changer in Dermatology · The Science of Skin

• 0:00
  SPEAKER_00: This episode is brought to you by Skin Suiticles, the number one medical aesthetic skincare brand worldwide, and the leader in antioxidant science.
• 0:08
  SPEAKER_00: To learn more, visit www.skinseuticals.com.
• 0:22
  SPEAKER_02: Hello and welcome to Skincare Confidential, a podcast supporting the Science of Skin Care Summit, an annual educational event occurring September 5th through the 7th in Austin, Texas, 2025.
• 0:34
  SPEAKER_02: My name is Dr.
• 0:35
  SPEAKER_02: Ted Lane.
• 0:36
  SPEAKER_02: I am a board certified dermatologist and your host for today.
• 0:39
  SPEAKER_02: But I am very excited to present my guest.
• 0:43
  SPEAKER_02: This is Dr.
• 0:44
  SPEAKER_02: Mark Lupin.
• 0:45
  SPEAKER_02: Mark is a dermatologist in Victoria, British Columbia.
• 0:49
  SPEAKER_02: He is also a clinical instructor at the University of British Columbia and the Chief Clinical Officer at MedSpa Partners, where he is also part of their multi-center clinical trials unit.
• 1:00
  SPEAKER_02: Although what we are going to talk about today, Mark, is a clinical trial that solely occurred at your site, correct?
• 1:07
  SPEAKER_01: Yes, that's correct, Ted.
• 1:09
  SPEAKER_01: And thank you very much for inviting me.
• 1:11
  SPEAKER_02: Oh, Mark, it is my pleasure.
• 1:12
  SPEAKER_02: Thank you so much for coming on.
• 1:14
  SPEAKER_02: So the reason that Mark is on with us today is first of all, he's a world-renowned dermatologist.
• 1:19
  SPEAKER_02: He's someone that I've known for quite some time, and I'm so happy to have you on with us, Mark, on our skincare podcast.
• 1:25
  SPEAKER_02: But we are talking about a trial that you performed with Skin Suiticals' new product called PTOx, which is a really revolutionary uh product containing multiple ingredients.
• 1:37
  SPEAKER_02: So I thought we could first dive into what PTOx is and how it works, and then how you used it in your very innovative and I have to say gutsy trial.
• 1:49
  SPEAKER_02: So let's let's start talking about PTOx, Mark.
• 1:53
  SPEAKER_02: What can you tell us about this new product?
• 1:56
  SPEAKER_01: Well, yes, thanks, uh Ted.
• 1:58
  SPEAKER_01: It was uh basically came uh as an innovation when we look at uh treatments with neuromodulator injections.
• 2:06
  SPEAKER_01: So, you know, we we can treat most areas, but there's some challenging areas such as under the eyes or what I call smile lines, uh parenthesis lines sort of around the cheeks and so forth.
• 2:17
  SPEAKER_01: So uh they they came up with this uh formulation which is actually has two neuropeptides.
• 2:23
  SPEAKER_01: Um one works at the presynaptic junction and one is postsynaptic.
• 2:27
  SPEAKER_01: And uh and then there's three other main ingredients, uh all of which are antioxidants.
• 2:32
  SPEAKER_01: Um three of those ingredients are laminaria extract, which is from brown seaweed, uh, which contains iodine or iodide, which is also an inorganic antioxidant, has uh polyhydroxy acids, um, which we know well, and also has some niacinamide.
• 2:47
  SPEAKER_01: Studies of trying to get topical neurotoxin-type uh moieties into the skin have uh generally not done so well.
• 2:56
  SPEAKER_01: So I thought it was also bold that they came up with this formulation.
• 2:59
  SPEAKER_02: Yeah, and so just to reiterate, right, it's got two kind of hero ingredients, which are the ingredients that work at the presynaptic junction to prevent acetylcholine from being released, and then at the postsynaptic junction to essentially prevent it from being from from having any activity.
• 3:18
  SPEAKER_02: Uh and so you can kind of think about this, especially the presynaptic level uh as a topical neurotoxin, can't you?
• 3:25
  SPEAKER_02: The way it's working on SNAP25 and the SNARE complex.
• 3:29
  SPEAKER_01: Yes, well, actually that first ingredient, acetylhexapeptide 8, and that's also called argiraline, and that's been around for 20 plus years.
• 3:39
  SPEAKER_01: And if you if you injected that into the skin, I think you would see uh sort of a definite change.
• 3:44
  SPEAKER_01: It basically uh is mimicking the N terminal of SNAP25, which we all know uh is the same molecule uh that uh botulinum toxins work with.
• 3:56
  SPEAKER_01: Um and so it's been around a long time.
• 3:58
  SPEAKER_01: Uh whether putting it topically does the same, but it will was part of how this study came about.
• 4:04
  SPEAKER_01: And the other uh neuropeptide, which is post synaptic, like you said, Ted, is is called dipeptide diaminobutyrol.
• 4:12
  SPEAKER_01: And um interestingly, that's related to venom from the temple viper snake, um, and it binds uh to the epsilon subunit of the acetylcholine receptor.
• 4:23
  SPEAKER_01: So it it basically prevents that from being activated.
• 4:27
  SPEAKER_02: Yeah.
• 4:28
  SPEAKER_02: So it's really it mimics the idea of a neuropeptide.
• 4:31
  SPEAKER_02: And I think the whole to me, the reason for this new cream, the PTOx, is that it's doing something that we try to do it with neuropeptides already, which is kind of this intradermal skin quality uh goal to improve very, very fine lines, to improve skin texture, redness, pore size.
• 4:54
  SPEAKER_02: But it's difficult to do that, right, Mark, with just free-handing intradermal injections of a very small amount of a neurotoxin, it's extra extremely difficult to do, and it's very difficult to replicate either between yourself or between yourself and another injector.
• 5:09
  SPEAKER_01: Absolutely.
• 5:10
  SPEAKER_01: I I think what you're referring is to is the microdroplet uh technique, which some people call me meso botox or meso.
• 5:18
  SPEAKER_01: Um and what's nice about this is patients are applying it, first of all.
• 5:22
  SPEAKER_01: Yeah.
• 5:22
  SPEAKER_01: Um, and also um it's more uniform.
• 5:26
  SPEAKER_01: So we could do microdroplet, but isn't it nice that you can have something uniform in a topical serum?
• 5:32
  SPEAKER_02: Yeah, and it gives you what they call a glass appearance to the skin, which you know makes a lot of appearance, makes a lot of sense, excuse me, as you think about its mechanism of action with these two novel peptides, because it really is kind of calming down the muscle activity of the skin at the very highest levels to give the texture a very, very even appearance.
• 5:51
  SPEAKER_02: Is did you see that in the clinical trials when you were seeing these patients back month after month?
• 5:57
  SPEAKER_01: Yes.
• 5:57
  SPEAKER_01: Well, fortunately, I've I've had the luxury of been able to do mesotype botox injections in the past, so to sort of compare, and you're quite right, uh, there's this sort of radiance uh glass skin uh is the the term.
• 6:11
  SPEAKER_01: And you know, I we wonder what's the mechanism because it can't just be muscles.
• 6:15
  SPEAKER_01: Um, some people think it's a balance between uh if you reduce the parasympathetic uh outflow, you allow the sympathetic to do better, which is maybe one reason pore size improves as well.
• 6:28
  SPEAKER_02: Okay, interesting.
• 6:29
  SPEAKER_02: Now, uh beyond those two, as you've already mentioned, there are a couple of other ingredients there.
• 6:34
  SPEAKER_02: Uh one of them is a polyhydroxic acid, like you mentioned, a 5% pH.
• 6:38
  SPEAKER_02: Now, pHs are very interesting uh alpha hydroxy acids.
• 6:41
  SPEAKER_02: They're they're they're bionic acids, right?
• 6:43
  SPEAKER_02: They're huge molecules, and they don't do much exfoliating, but maybe just enough that that's all we need for the purpose of this cream.
• 6:53
  SPEAKER_01: Yes.
• 6:54
  SPEAKER_01: Well, you know, uh we can get into the study, but basically I was, you know, as a dermatologist, you you want to make to make sure that whatever serum you have is not exfo not peeling, not irritating, especially in the delicate areas, and and it performs perfectly.
• 7:10
  SPEAKER_01: Um so I I think it would be more in the it's more like a glucono lactone rather than a glycolic.
• 7:15
  SPEAKER_01: Yeah.
• 7:15
  SPEAKER_01: And it performs very gently that way.
• 7:17
  SPEAKER_02: Yeah, yeah, there you go.
• 7:18
  SPEAKER_02: And then you've got the laminaria, which is a very strong antioxidant, you meant as you mentioned, and the 5% niacinamide, which we know is kind of the gentle giant of ingredients.
• 7:27
  SPEAKER_02: It can do so many things, including helping repair the barrier.
• 7:31
  SPEAKER_02: So, so okay, I I feel like we've really dived into the the ingredients underlying the the use of PTox and how it's so novel a combination.
• 7:41
  SPEAKER_02: Let's go into your study in particular, Mark.
• 7:44
  SPEAKER_02: So so you took you took entire faces, right?
• 7:47
  SPEAKER_02: Of of females in particular, I believe.
• 7:49
  SPEAKER_02: Is that right?
• 7:50
  SPEAKER_01: Yes, it was actually we had males as well, thank goodness.
• 7:54
  SPEAKER_02: Okay.
• 7:54
  SPEAKER_01: Uh and it was Fitzpatrick one to six, so all phenotypes.
• 7:59
  SPEAKER_02: Okay, great.
• 8:00
  SPEAKER_02: And you did uh 40 subjects, right?
• 8:03
  SPEAKER_02: 40 male and female subjects, 38 to 70 years of age.
• 8:06
  SPEAKER_01: Yes.
• 8:07
  SPEAKER_01: And that which is pretty typical of most practices.
• 8:10
  SPEAKER_02: Yeah, right.
• 8:11
  SPEAKER_02: And and you said, okay, look, we're going to give them a treatment of a neurotoxin to their crow's feet and their glabella, which is the glabella is the number 11 between the eyebrows.
• 8:21
  SPEAKER_02: It's it's the first area that received an FDA approved indication for Botox, for example.
• 8:28
  SPEAKER_02: Uh, and you're gonna treat both crow's feet, both eyes, and the glabella.
• 8:32
  SPEAKER_02: But otherwise, you're gonna split the face in half.
• 8:34
  SPEAKER_02: And on one half of the face, you'll treat it with the PTOX, and on the other half you'll treat it just with the vehicle.
• 8:41
  SPEAKER_02: So just essentially with everything except the active ingredients that we mentioned.
• 8:45
  SPEAKER_02: And patients were to treat that daily, and this was uh about an eight-week study uh after the the run-in with the pretreatment.
• 8:53
  SPEAKER_02: So they really had a good amount of time for us to see the effect of the topical.
• 8:58
  SPEAKER_01: Yes, and um what was great is they used the topical alone uh for two weeks before the injections.
• 9:05
  SPEAKER_01: So we could sort of see, well, was there an early sign or signal first tolerability, and two, uh was there so clinical effect, you know, even before the treatments?
• 9:15
  SPEAKER_01: And and the study did show uh extremely well tolerated, and also there was an early clinical improvement.
• 9:21
  SPEAKER_01: And it was a double-blind, randomized controlled study.
• 9:25
  SPEAKER_01: So I didn't know what they were using, and the patients didn't know, and they were often guessing, uh, even my staff were guessing, and uh it was pretty hard to know.
• 9:33
  SPEAKER_01: So I think it was a it was a well-done study from that perspective.
• 9:37
  SPEAKER_02: Well, and what you know, I really think this is a gutsy study because especially when you're thinking about those fine lines around the eyes, you would imagine that almost all of the improvement would be due to the neurotoxin treatment.
• 9:48
  SPEAKER_02: I mean, you're literally injecting, you know, 12 plus units of a not of a toxin around the eyes.
• 9:54
  SPEAKER_02: Uh, and and you wouldn't think that topically applied neuropeptides would add that much in terms of the appearance of the fine lines around the eyes after a neurotoxin treatment.
• 10:05
  SPEAKER_01: You're quite right.
• 10:06
  SPEAKER_01: And you know, in a way, I was relieved uh that it was that it that it wasn't too effective, like you know, it was extremely effective for what patients were coming in for, which is lines, wrinkles, radiance, uh, pigmentation, all sorts of things.
• 10:20
  SPEAKER_01: Um, but I was actually relieved that it didn't uh that the if the effect is uh to do with the neuropeptides, it seems more like a meso effect.
• 10:28
  SPEAKER_01: Yeah.
• 10:28
  SPEAKER_01: And so so for me that was that was actually thrilling.
• 10:31
  SPEAKER_01: It didn't have to worry about allitosis or any anything additional, uh, or treating muscles you don't want to treat.
• 10:38
  SPEAKER_01: So it was really satisfying.
• 10:41
  SPEAKER_02: That that's a really good point.
• 10:42
  SPEAKER_02: So as we kind of look at the uh effective efficacy, right?
• 10:46
  SPEAKER_02: I'm just looking at some of these numbers here where we look at the improvement and lateral canthal lines.
• 10:51
  SPEAKER_02: So this is mean improvement from baseline, and and I'm looking at a graph, and we could we'll show this on the on our video.
• 10:58
  SPEAKER_02: Uh the graph has got uh lateral canthal lines and globellar lines looking at day zero, week two, four, and eight.
• 11:05
  SPEAKER_02: And especially as you look at week eight with the PTox treated side versus the control treated side, and again, both sides were treated with neurotoxins, so so we know that they were both treated, but in terms of topically what they what was being applied, we see that there's a there's a statistically significant difference actually in the mean improvement from baseline in the appearance of those crow's feet or those lateral canthalines between the side treated with PTOX versus the side treated with vehicle or control.
• 11:34
  SPEAKER_02: Again, amazing.
• 11:36
  SPEAKER_01: Yes, and you know, you and I are both clinicians and science scientists, so we don't expect these things really.
• 11:42
  SPEAKER_01: Uh and and and so to to see something, uh there were actually 19 different skin qualities, you know, and and actually the they all reached P less than 0.05, you know, for statistical uh uh substance.
• 11:57
  SPEAKER_01: So it's actually um amazing that uh that it really did add.
• 12:01
  SPEAKER_01: And you know, patients uh also want something safe that they can use, or a technician want to recommend something safe around injectable treatments like this.
• 12:11
  SPEAKER_01: So I think the fact that it was done uh not uh in real life, like sort of a real case type of scenario.
• 12:17
  SPEAKER_01: Um yeah, no, I I I I didn't expect these results uh to be, it was not till afterwards that they shared it with me.
• 12:24
  SPEAKER_01: And okay, um it sort of matched the an impression that once I was was doing better.
• 12:30
  SPEAKER_02: Oh, that's incredible.
• 12:31
  SPEAKER_02: And and we see the same on the globelled lines as well.
• 12:34
  SPEAKER_02: Again, treated with Botox or with a neurotoxin, we definitely see a difference statistically significant at week eight between the the the PTox side versus the vehicle side.
• 12:44
  SPEAKER_02: And then as you mentioned, as we go through forehead wrinkles, under-eye wrinkles, nasal, the the bunny lines on the nose, the cheek folds, uh oral commissures, we see again these these areas were not treated with a neurotoxin, these areas were just treated with PTOX or the vehicle.
• 13:04
  SPEAKER_02: But we see very significant differences between the appearance and then global fine lines, 33% change from baseline with the PTOX versus 16.5% with the vehicle.
• 13:15
  SPEAKER_02: So it doubles what essentially a moisturizing vehicle can do.
• 13:19
  SPEAKER_02: So gosh, we really see the efficacy of these five actives that are working together.
• 13:25
  SPEAKER_01: Definitely.
• 13:25
  SPEAKER_01: You know, uh interestingly, the two neuropeptides also have antioxidant uh capabilities.
• 13:32
  SPEAKER_01: So in a way, we have uh five antioxidants, uh plus two of which are also neuropeptides and maybe conferring a meso type of uh an effect.
• 13:41
  SPEAKER_01: I the other quality I liked was uh healthy look, healthy appearance was one of the attributes.
• 13:49
  SPEAKER_01: And uh and even that was statistically different uh or improved on the PTox side.
• 13:54
  SPEAKER_02: Yeah, as as early as day zero, actually, you see a difference.
• 13:58
  SPEAKER_02: So again, you had that two-week run-in where the patients were had already split the face and were using PTox versus vehicle, and we see double the number of per amount of of improvement at day zero between the two.
• 14:11
  SPEAKER_01: Yes, definitely.
• 14:12
  SPEAKER_01: The other thing, I mean, you might expect this, but pigmentation improved.
• 14:16
  SPEAKER_01: It could be niacinamide, uh, of course, and uh some of the other, but we saw pigmentation improve.
• 14:22
  SPEAKER_01: Patients with uh sort of slight rosacea tendency tolerated extremely well.
• 14:27
  SPEAKER_01: And you know, they were applying the serum completely around the face, including the eyelids, upper and lower.
• 14:33
  SPEAKER_01: Uh like there was just uh in fact, we didn't we didn't advise them to apply it on their upper eyelids.
• 14:38
  SPEAKER_01: We said just apply it underneath.
• 14:39
  SPEAKER_01: Uh, but you know, they come back and they use it everywhere, and no and no issues from a safety perspective and extremely well tolerated.
• 14:49
  SPEAKER_01: So yeah, the pigmentation, the skin quality.
• 14:52
  SPEAKER_01: And you know, this is just a single center study.
• 14:55
  SPEAKER_01: It was fortunately double blind, randomized, and split face.
• 14:58
  SPEAKER_01: But you know, as time will tell, um how how this might fit in.
• 15:03
  SPEAKER_01: And you know, you you 40 patients is fantastic, but you need obviously big need bigger numbers to resonate even more.
• 15:10
  SPEAKER_02: Yeah, but seeing that kind of statistical significance even with 40 patients is really incredible.
• 15:15
  SPEAKER_02: So, so Mark, congratulations on a really well-done study.
• 15:18
  SPEAKER_02: I think the protocol makes a lot of sense and and how it was was performed, uh, really highlights the efficacy of this product and how it really can be used along with a neurotoxin and and amplifies the benefits of a neurotoxin in the treatment areas, but then mimics those effects across the skin surface through that kind of meso uh neurotoxin effect, as you mentioned.
• 15:44
  SPEAKER_02: So, so congratulations, what a great study.
• 15:47
  SPEAKER_01: No, just just lucky.
• 15:49
  SPEAKER_01: Lucky, but but thanks so much for highlighting it.
• 15:55
  SPEAKER_00: This episode is brought to you by Skin Suiticals, the number one medical aesthetic skincare brand worldwide, and the leader in antioxidant science.
• 16:04
  SPEAKER_00: To learn more, visit www.skinseuticals.com.
• 16:11
  SPEAKER_02: Listen, we have a few minutes left, and I think that there is, you know, I I just learned this about you, Dr.
• 16:16
  SPEAKER_02: Lupin, that that you were a neurologist before you were a dermatologist.
• 16:20
  SPEAKER_02: So, you know, we're talking about all these neurotoxins and effects on nerves, and here we are speaking to a neurodermatologist.
• 16:27
  SPEAKER_01: Well, it goes, I mean, I studied neurology, then dermatology, and then my wife said that's enough.
• 16:34
  SPEAKER_01: Uh more more or less.
• 16:36
  SPEAKER_01: Um and then the other thing is that we're I'm in Victoria, which is near Vancouver, and studied at UBC Department of Dermatology, and that's sort of the epicenter of where cosmetic use of botulinum toxin or botoxin is.
• 16:50
  SPEAKER_01: Right.
• 16:50
  SPEAKER_01: So um, and in fact, I was using it in the new in my neurology residency to treat dystonias uh before I met the Carruthers, Alistair Carruthers, Dr.
• 17:01
  SPEAKER_01: Carruthers, um, and then Jean, because Dr.
• 17:04
  SPEAKER_01: Alastair Carruthers was my was my uh one of my teachers as part of as a DOM resident.
• 17:10
  SPEAKER_02: Uh-huh.
• 17:10
  SPEAKER_01: So it was it was nice to share with him some of my neurology experience um and combined with what they were just discovering uh seredipitously with the cosmetic side.
• 17:22
  SPEAKER_02: Now, when you were using it for neurological purposes, did you also notice a change in the skin?
• 17:27
  SPEAKER_02: Was this something that that many people had said, oh wow, yeah, I see there's some change, or or had you not, it wasn't part of what you were looking for?
• 17:35
  SPEAKER_01: Yeah, well, in my case, I I was working with focal dystonius, like uh because I'm I'm a musician, I'm a violinist, so I was working with pianists who and so yeah, we weren't looking at the skin.
• 17:46
  SPEAKER_02: Not looking at the skin at all.
• 17:48
  SPEAKER_01: We were just hoping they could still play the piano.
• 17:50
  SPEAKER_02: Yeah, okay, gotcha.
• 17:52
  SPEAKER_02: Uh okay, and so and what made you decide dermatology then?
• 17:56
  SPEAKER_02: Why why go into derm?
• 17:58
  SPEAKER_01: Well, I love all of medicine, you know, it's pretty hard.
• 18:01
  SPEAKER_01: I'm sure you had may have had maybe you do, maybe you were born to be a dermatologist, but uh um no, I'm a classical violinist, you know, concert violinist.
• 18:11
  SPEAKER_01: I'm still performing, and actually I love neurology, but it was becoming more interventional.
• 18:16
  SPEAKER_01: Um and then uh dermatology just gives a bit more flexibility to to have a continue a career with with a with violin, with classical work.
• 18:26
  SPEAKER_01: So partly it was practical, partly it's like everything.
• 18:30
  SPEAKER_01: And uh, you know, it's ultimately when we can help our patients.
• 18:33
  SPEAKER_01: Um that's that's the ultimate meaning of medicine.
• 18:37
  SPEAKER_02: Absolutely.
• 18:37
  SPEAKER_02: And so you still are performing as a violinist, you still have the time to do that?
• 18:43
  SPEAKER_01: Well, barely.
• 18:43
  SPEAKER_01: But uh yes, I'm consummate of the World Doctors Orchestra, which is based in Berlin, but they do about four concerts a year.
• 18:50
  SPEAKER_01: We're playing at Carnegie Hall this year, um, in the fall, and it's all for charity, so it's sort of a good feel.
• 18:58
  SPEAKER_01: And then uh I study with a well-known violinist called Yascha Heifitz in California, so I'm actually still in touch with his pianist, and so we do violin piano uh work as well, recitals.
• 19:11
  SPEAKER_02: Okay.
• 19:11
  SPEAKER_02: And okay, so so you are a full-time dermatologist, you do research, you're the chief clinical officer of a large group in Canada, and you also are a concert violinist and the concertmaster for the World Doctors Orchestra.
• 19:24
  SPEAKER_02: So uh I'm not gonna ask what else you do because that's just gonna make me feel bad about myself, actually.
• 19:29
  SPEAKER_01: So No, no.
• 19:30
  SPEAKER_01: Well, I was gonna reverse the table and ask you what you know, tell me about you.
• 19:35
  SPEAKER_01: But maybe there's not enough time.
• 19:36
  SPEAKER_01: I'm sure there's lots to you know, we all have interesting uh backgrounds.
• 19:40
  SPEAKER_02: Yeah, it's interesting, Mark.
• 19:41
  SPEAKER_02: I I did not know the neurology part.
• 19:44
  SPEAKER_02: I hadn't I had an idea about the the concert violinists just because I've I've heard you speak about uh music before with such passion.
• 19:51
  SPEAKER_02: So I knew you had you were very involved in music.
• 19:54
  SPEAKER_02: I wasn't sure at what capacity.
• 19:56
  SPEAKER_02: Uh and so if we want to learn more about the World Doctors Orchestra, where would we go to find out more about that?
• 20:02
  SPEAKER_01: Well, I think if you just uh Google World Doctors Orchestra, they have their own dedicated website.
• 20:07
  SPEAKER_01: Okay.
• 20:07
  SPEAKER_01: Um and it's actually it's actually fantastic because there's over 3,000 members from 60 different countries and about a hundred perform each time, and all the proceeds go to local and international charities.
• 20:21
  SPEAKER_01: So it's been around for quite a few years, as of as have I.
• 20:27
  SPEAKER_01: But uh and they have quite a USA uh presence, they have an international presence, um, but they have a USA um dedicated um uh section, if you like.
• 20:38
  SPEAKER_01: Okay.
• 20:39
  SPEAKER_01: Uh which is partly why we tend to play it as well in the United States a fair amount.
• 20:43
  SPEAKER_02: Well, well, listen, congratulations, and good luck on your on your upcoming Carnegie Hall performance.
• 20:47
  SPEAKER_02: When will that be?
• 20:49
  SPEAKER_01: That's in November.
• 20:50
  SPEAKER_02: November of 2020.
• 20:52
  SPEAKER_01: I don't remember the don't remember the dates, but it's okay.
• 20:54
  SPEAKER_02: We can we can find it online.
• 20:56
  SPEAKER_02: World Doctors Orchestra, Dr.
• 20:57
  SPEAKER_02: Mark Loop, and Concertmaster, we'll find it, we'll find it online.
• 21:01
  SPEAKER_02: Now, Mark, we've only got a couple of minutes left, but I'd like to ask you, just because you really are at the cutting edge of of cosmetic dermatology, of aesthetic dermatology, uh, what are you most excited about that that you see you know in the pipeline should be approved in the next couple of years?
• 21:18
  SPEAKER_02: Is there anything that you see that that really it's is is something that scientifically is is a breakthrough or or otherwise is an iterative improvement that you're ready to start using for your patients?
• 21:31
  SPEAKER_01: That's a really good question.
• 21:33
  SPEAKER_01: Because there's so many, I mean, people talk about regenerative medicine a lot and exosomes and all this.
• 21:38
  SPEAKER_01: So I I mean I think this concept is good.
• 21:41
  SPEAKER_01: I would like to see something uh that's sort of uh well proven from a safety perspective.
• 21:46
  SPEAKER_01: Um but that could be a a breakthrough in the sense that if we could have um ways to promote uh the skin to be the best it can be, which we in a way have with antioxidants and retinoids and some of the treatments.
• 22:00
  SPEAKER_01: I uh technology-wise, I've been most excited about laser coring.
• 22:05
  SPEAKER_01: Um because my one of my passions is scar revision, and uh I think you can do amazing things with that.
• 22:13
  SPEAKER_02: Okay.
• 22:14
  SPEAKER_02: Have you been seeing that already in your clinic with the laser coring?
• 22:17
  SPEAKER_01: Yes, yeah, definitely.
• 22:18
  SPEAKER_01: And it's already they're already approved devices and they they they're they're they're just getting better.
• 22:23
  SPEAKER_02: Oh, wonderful.
• 22:24
  SPEAKER_02: See, okay.
• 22:25
  SPEAKER_02: There we go, guys.
• 22:26
  SPEAKER_02: We just learned something about laser coring, and of course, regenerative medicine will keep everyone up to date.
• 22:31
  SPEAKER_02: There's a lot changing in that.
• 22:33
  SPEAKER_02: Uh Dr.
• 22:34
  SPEAKER_02: Lupin, thank you so much for your time and for again letting us walk through this study that you did on that skin suiticals PTox uh along with a neuropepti neuro uh excuseptide.
• 22:46
  SPEAKER_02: It has neuropeptides.
• 22:48
  SPEAKER_02: That's it.
• 22:49
  SPEAKER_02: Yeah.
• 22:50
  SPEAKER_02: Uh along with uh a Botox-like treatment uh to even enhance the efficacy of that and to improve the appearance of fine lines as well as skin health and skin beauty across the face.
• 23:04
  SPEAKER_02: Um, I really appreciate it.
• 23:05
  SPEAKER_02: Thank you so much for being with us.
• 23:06
  SPEAKER_01: Thank you, Ted.
• 23:07
  SPEAKER_01: It's been a real honor and a pleasure.
• 23:09
  SPEAKER_01: Thanks so much.
• 23:10
  SPEAKER_02: No problem.
• 23:10
  SPEAKER_02: I am Dr.
• 23:11
  SPEAKER_02: Ted Lane.
• 23:11
  SPEAKER_02: You have listened to Skincare Confidential.
• 23:14
  SPEAKER_02: Please, if you've enjoyed this podcast, subscribe, uh, give us a five star rating, and refer us to all of your friends.
• 23:21
  SPEAKER_02: Thank you so much.
• 23:24
  SPEAKER_00: This episode is brought to you by Skin Suticles, the number one medical aesthetic skincare brand worldwide, and the leader in antioxidant science.
• 23:33
  SPEAKER_00: To learn more, visit www.skinseuticals.com.